Postoperative Monitoring: Biomarkers and Alloimmune Responses and Their Relevance to Vascularized Composite Allotransplantation

Biomarkers Definitions Working, G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. Hartono C, Muthukumar T, Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant. 2010;15(1):35–41. Domenig C, Sanchez-Fueyo A, Tian Y, et al. The role of immunoregulatory networks in tolerant mixed chimeras induced by a non-myeloablative irradiation free protocol. Am J Transplant. 2003;3(Supplement s5):156. Lechler RI, Batchelor JR. Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J Exp Med. 1982;156(6):1835–41. Batchelor JR, Lechler RI. Why MHC incompatible grafts induce strong primary alloimmunity. Transplant Proc. 1982;14(3):535–7. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med. 1982;155(1):31–41. van Besouw NM et al. The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation. Clin Exp Immunol. 2005;141(3):534–40. Baker RJ et al. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol. 2001;167(12):7199–206. Vella JP et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation. 1997;64(6):795–800. Sayegh MH, Carpenter CB. Role of indirect allorecognition in allograft rejection. Int Rev Immunol. 1996;13(3):221–9. Strom TB, Koulmanda M. Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol. 2009;20(8):1677–80. Korn T et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448(7152):484–7. Bettelli E et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–8. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol. 2009;9(12):883–9. Mitchell P et al. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant. 2009;14(4):326–31. Segall M et al. Lack of correlation of MLC reactivity with acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation. Hum Immunol. 1996;49(1):49–55. Hernandez-Fuentes MP, Salama A. In vitro assays for immune monitoring in transplantation. Methods Mol Biol. 2006;333:269–90. van Besouw NM et al. The granzyme B and interferon-gamma enzyme-linked immunospot assay as alternatives for cytotoxic T-lymphocyte precursor frequency after renal transplantation. Transplantation. 2005;79(9):1062–6. Kreijveld E et al. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS One. 2008;3(7):e2711. van der Mast BJ et al. Calcineurin inhibitor withdrawal in stable kidney transplant patients decreases the donor-specific cytotoxic T lymphocyte precursor frequency. Transplantation. 2005;80(9):1220–5. Steinmann J et al. Failure of in vitro T-cell assays to predict clinical outcome after human kidney transplantation. J Clin Lab Anal. 1994;8(3):157–62. van Besouw NM et al. After discontinuation of calcineurin inhibitors, tapering of mycophenolate mofetil further impairs donor-directed cytotoxicity. Clin Transplant. 2008;22(2):129–35. Gebauer BS et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant. 2002;2(9):857–66. Nather BJ et al. Modified ELISPOT technique--highly significant inverse correlation of post-Tx donor-reactive IFNgamma-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients. Transpl Immunol. 2006;16(3–4):232–7. Heeger PS et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol. 1999;163(4):2267–75. Volk HD, Kern F. Insights into the specificity and function of (allo)antigen-reactive T cells. Am J Transplant. 2001;1(2):109–14. Couzi L et al. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. Transplantation. 2008;86(8):1060–7. Kowalski RJ et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82(5):663–8. Hricik DE et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant. 2003;3(7):878–84. Nickel P et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation. 2004;78(11):1640–6. Augustine JJ et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol. 2007;18(5):1602–6. Andree H et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol. 2006;17(2):573–80. Poggio ED et al. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol. 2006;17(2):564–72. Schlaf G et al. Soluble CD30 serum level–an adequate marker for allograft rejection of solid organs? Histol Histopathol. 2007;22(11):1269–79. Saini D et al. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant. 2008;8(9):1798–808. Platt RE et al. Soluble CD30 as a prognostic factor for outcome following renal transplantation. J Clin Pathol. 2009;62(7):662–3. Slavcev A et al. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft. Transpl Immunol. 2007;18(1):22–7. Petruzzo P, Dubernard JM. The international registry on hand and composite tissue allotransplantation. Clin Transpl. 2011;247–53. Creemers P et al. Evaluation of peripheral blood CD4 and CD8 lymphocyte subsets, CD69 expression and histologic rejection grade as diagnostic markers for the presence of cardiac allograft rejection. Transpl Immunol. 2002;10(4):285–92. Trzonkowski P et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant. 2008;8(2):338–47. Pearl JP et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005;5(3):465–74. Ticha O et al. Monitoring of CD38high expression in peripheral blood CD8+ lymphocytes in patients after kidney transplantation as a marker of cytomegalovirus infection. Transpl Immunol. 2010;24(1):50–6. Hautz T et al. Histopathologic characterization of mild rejection (grade I) in skin biopsies of human hand allografts. Transpl Int. 2012;25(1):56–63. Kanitakis J et al. Clinicopathologic monitoring of the skin and oral mucosa of the first human face allograft: report on the first eight months. Transplantation. 2006;82(12):1610–5. Landin L et al. CD3+-mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab. Transplantation. 2009;87(5):776–81. van Besouw NM et al. The frequency of interferon-gproducing cells reflects alloreactivity against minor histocompatibility antigens. Transplantation. 2003;75(8):1400–4. Poggio ED et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol. 2004;15(7):1952–60. Bestard O et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol. 2008;19(7):1419–29. Li B et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med. 2001;344(13):947–54. Muthukumar T et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med. 2005;353(22):2342–51. Strehlau J et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A. 1997;94(2):695–700. Pavlakis M et al. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation. 1996;62(4):543–5. Lipman ML, Stevens AC, Strom TB. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol. 1994;152(10):5120–7. Nickel P et al. Cytotoxic effector molecule gene expression in acute renal allograft rejection: correlation with clinical outcome; histopathology and function of the allograft. Transplantation. 2001;72(6):1158–60. Hoffmann SC et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant. 2005;5(3):573–81. Mengel M et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant. 2009;9(8):1859–67. Reeve J et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant. 2009;9(8):1802–10. Barker AK et al. Combined analysis of allograft inflammatory factor-1, interleukin-18, and Toll-like receptor expression and association with allograft rejection and coronary vasculopathy. Am Surg. 2010;76(8):872–8. Luan FL et al. A pilot study of gene expression-based categorization of pancreas transplant biopsies. Transplantation. 2009;87(2):222–6. Minisini R et al. Early activation of interferon-stimulated genes in human liver allografts: relationship with acute rejection and histological outcome. J Gastroenterol. 2011;46(11):1307–15. Asaoka T et al. MicroRNA signature of intestinal acute cellular rejection in formalin-fixed paraffin-embedded mucosal biopsies. Am J Transplant. 2012;12(2):458–68. Sui W et al. Microarray analysis of MicroRNA expression in acute rejection after renal transplantation. Transpl Immunol. 2008;19(1):81–5. Chen HY et al. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol. 2012;29(3):1859–65. Sabek O et al. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation. 2002;74(5):701–7. Simon T et al. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant. 2003;3(9):1121–7. Sawitzki B et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant. 2007;7(5):1091–102. Bohne F et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest. 2012;122(1):368–82. First prospective immunosuppression withdrawal trial in which tissue gene expression measurements accurately predicted the outcome of immunosuppresion withdrawal. Farid WR et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl. 2012;18(3):290–7. Madsen CB et al. Elevated mRNA levels of CTLA-4, FoxP3, and granzyme B in BAL, but not in blood, during acute rejection of lung allografts. Transpl Immunol. 2010;24(1):26–32. Snyder TM et al. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A. 2011;108(15):6229–34. A promising noninvasive technique to diagnose rejection in difficult to access transplanted tissues & organs. Oellerich M et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit. 2014;36(2):136–40. Sommerer C et al. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant. 2009;24(1):21–7. Hooper E et al. Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant. 2005;19(6):834–9. Gralla J, Huskey J, Wiseman AC. Trends in immune function assay (ImmuKnow; Cylex) results in the first year post-transplant and relationship to BK virus infection. Nephrol Dial Transplant. 2012;27(6):2565–70. Berger SP et al. Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant. 2005;5(6):1361–6. Carroll KE et al. High levels of mannose-binding lectin are associated with poor outcomes after lung transplantation. Transplantation. 2011;91(9):1044–9. Manuel O et al. Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency. Transpl Infect Dis. 2007;9(3):214–8. Docke WD et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678–81. Crockard AD et al. Methylprednisolone attenuates interferon-beta induced expression of HLA-DR on monocytes. J Neuroimmunol. 1996;70(1):29–35. Koppelman B et al. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity. 1997;7(6):861–71. Haveman JW et al. Low HLA-DR expression on peripheral blood monocytes predicts bacterial sepsis after liver transplantation: relation with prednisolone intake. Transpl Infect Dis. 1999;1(3):146–52. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3(3):199–210. Bennett CL et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27(1):20–1. Walker MR et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest. 2003;112(9):1437–43. Roncador G et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol. 2005;35(6):1681–91. Ziegler SF. FOXP3: not just for regulatory T cells anymore. Eur J Immunol. 2007;37(1):21–3. Seddiki N et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203(7):1693–700. Liu W et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701–11. Bestard O et al. Intragraft regulatory T cells in protocol biopsies retain foxp3 demethylation and are protective biomarkers for kidney graft outcome. Am J Transplant. 2011;11(10):2162–72. Akl A et al. An investigation to assess the potential of CD25highCD4+ T cells to regulate responses to donor alloantigens in clinically stable renal transplant recipients. Transpl Int. 2008;21(1):65–73. Louis S et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation. 2006;81(3):398–407. Braudeau C et al. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int. 2007;20(10):845–55. Li Y et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant. 2004;4(12):2118–25. Martinez-Llordella M et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant. 2007;7(2):309–19. van de Wetering J et al. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation. Clin Transplant. 2011;25(1):40–6. Mazariegos GV et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant. 2003;3(6):689–96. Martinez-Llordella M et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest. 2008;118(8):2845–57. Lee WP et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg. 1991;87(3):401–11. Cendales LC et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant. 2008;8(7):1396–400. Kanitakis J. The challenge of dermatopathological diagnosis of composite tissue allograft rejection: a review. J Cutan Pathol. 2008;35(8):738–44.